Breaking News

Cancer therapy’s new ‘gold rush’: bispecific antibodies that hit key combination of targets 

January 22, 2025
Pharmalot Columnist, Senior Writer
Bispecific antibodies that bind to a PD-1 molecule as well as a VEGF protein have shown promise against cancers.
Adobe

STAT+ | Cancer therapy's new 'gold rush': bispecific antibodies that hit key combination of targets

Recent results with bispecific antibodies that target VEGF and PD-1 proteins raise hope of new "pan-tumor platform" like Keytruda.

By Angus Chen


Opinion: Medicare drug price negotiations need something new: a floor

Setting a floor that reflects the value of a drug to patients would reward innovators for improving patients' lives.

By Darius Lakdawalla


STAT+ | Eleos raises $60 million for AI scribe for behavioral health providers

Eleos Health, which makes software that generates clinical notes from the audio of behavioral health appointments, has raised $60 million.

By Mario Aguilar



More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.

No comments